Bristol-Myers Squibb is focused on addressing the significant unmet medical needs of patients with chronic viral disease and related illnesses. We concentrate our efforts on hepatitis B and C, and HIV/AIDS, where we seek significant improvements in cure rates, survival and quality of life.
Hepatitis B and C are the most significant forms of this frequently fatal disease of the liver. The most common of all serious liver infections, hepatitis B, kills approximately 600,000 people a year. Of the more than two billion people infected globally, the World Health Organization reports that about 350 million have chronic hepatitis B virus, which can cause cirrhosis and liver cancer.
The World Health Organization estimates that 170 million people are chronically infected with hepatitis C, and approximately three to four million persons are newly infected each year. Like chronic hepatitis B, chronic hepatitis C viral infection can lead to serious complications, such as cirrhosis and liver cancer, and can necessitate liver transplantation.
While scientists have developed some effective therapies in recent years for hepatitis B and C, significant unmet medical needs still exist as a result of problems related to potency, resistance, and tolerability. Recognizing these needs, we are working to provide new treatments for both forms of this very widespread, highly infectious disease.
HIV/AIDS is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV). HIV interferes with the body’s immune system, damaging its ability to effectively fight off viruses, bacteria and fungi. This damaged immune system puts patients more at risk to dangerous infections the body would normally resist and certain types of cancer.
When acquired immune deficiency syndrome (AIDS) was first identified about 25 years ago, there were few treatment options. Now, while there are still no cures, drug treatments have turned HIV into a treatable disease for many. Today there are 33.3 million people living with HIV/AIDS around the world, according to the Joint United Nations Programme on HIV/AIDS.
Bristol-Myers Squibb has long been a leader in developing innovative HIV/AIDS medications and treatments and will continue to make HIV/AIDS research a priority.
Our company allocates substantial R&D resources to developing new medicines and treatments in the global fight against HIV/AIDS. We are exploring new ways to attack the AIDS virus and new ways to help make treatments simpler for patients to take.